X, the most widely used app for crypto projects, is changing its API access policy. InfoFi projects, which proliferated non-organic bot content, will be cut offX, the most widely used app for crypto projects, is changing its API access policy. InfoFi projects, which proliferated non-organic bot content, will be cut off

X to cut off InfoFi crypto projects from accessing its API

X, the most widely used app for crypto projects, is changing its API access policy. InfoFi projects, which proliferated non-organic bot content, will be cut off from the social network. 

X cut API access to InfoFi projects, after a period of increased non-organic traffic with AI-based content. InfoFi was another use case for on-chain activity, which still relied on the traditional X feed. Users were rewarded for posting, and ended up overloading the social media platform with AI-generated content. 

In another round of reinventing the X relationship with crypto content, the site’s product manager, Nikita Bier, explained the changes coming for InfoFi projects. The changes effectively ban rewards for posting, especially for explicit promises to earn points or airdrop access.

The changes come just a day after X boosted exposure to crypto projects through cashtags, offering more accurate labeling for projects and tickers.  

The changes came after the crypto community accused X of decreasing reach for crypto projects, apps, and influencers. In the past year, some projects complained of lower reach, while X tried to fight scams and low-quality content. 

InfoFi tokens crash after X ban

Immediately after the news of the API ban, almost all InfoFi tokens wiped out a part of their value. The overall market is small, valued at under $400K, reflecting the relative novelty of InfoFi projects. 

X cuts down InfoFi projects with AI-generated contentKAITO crashed immediately after the news that InfoFi projects will loose access to X API. No more rewards for posting are allowed, to keep the social network from spam and AI-generated posts. | Source: Coingecko

In the past day, the whole token class crashed by 11.6%, with near-vertical losses immediately after Bier’s statement. KAITO, one of the leading InfoFi and mindshare apps, lost 15.2% to trade near its lowest range at $0.57.

ZachXBT criticized InfoFi campaigns

ZachXBT has been tracking various InfoFi campaigns, believing they harmed the crypto community rather than popularizing the projects. 

While Kaito offered useful data on influence, it also encouraged frequent posting that bloated the content in the crypto space. 

InfoFi creation followed a previous attempt to rebuild social media for niche projects. However, InfoFi apps decided to use the exposure of X, the most widely used social network. 

The recent API ban showed that even projects claiming to be decentralized relied heavily on Web2 rails for their exposure. 

Before the ban, InfoFi projects spent widely on API access and encouraged posting as a way of farming airdrop points. The Kaito airdrop was the most notorious case, later establishing multiple circles of influencers. 

Soon after the ban, InfoFi faced an uncertain fate. For some, Kaito and other apps were doomed to be abandoned, similar to FriendTech apps. For others, InfoFi would seek ways to adapt and find more favorable platforms or new tasks for point farming, such as testnet usage.

Don’t just read crypto news. Understand it. Subscribe to our newsletter. It's free.

Market Opportunity
RWAX Logo
RWAX Price(APP)
$0.0002166
$0.0002166$0.0002166
0.00%
USD
RWAX (APP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26